相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition
Yuji Piao et al.
CLINICAL CANCER RESEARCH (2013)
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
Shota Tanaka et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges
Gazanfar Rahmathulla et al.
ONCOTARGETS AND THERAPY (2013)
Antiangiogenic Therapy for Patients with Recurrent and Newly Diagnosed Malignant Gliomas
Katsuyuki Shirai et al.
JOURNAL OF ONCOLOGY (2012)
Bevacizumab Does Not Increase the Risk of Remote Relapse in Malignant Glioma
Antje Wick et al.
ANNALS OF NEUROLOGY (2011)
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2010)
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
Roger Stupp et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
John F. de Groot et al.
NEURO-ONCOLOGY (2010)
SAFETY AND EFFICACY OF BEVACIZUMAB WITH HYPOFRACTIONATED STEREOTACTIC IRRADIATION FOR RECURRENT MALIGNANT GLIOMAS
Philip H. Gutin et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas
Michael L. H. Wong et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
Eudocia C. Quant et al.
NEURO-ONCOLOGY (2009)
Antiangiogenic Strategies for Treatment of Malignant Gliomas
Andrew S. Chi et al.
NEUROTHERAPEUTICS (2009)
Angiogenesis as a Therapeutic Target in Malignant Gliomas
Andrew S. Chi et al.
ONCOLOGIST (2009)
FDA Drug Approval Summary: Bevacizumab (Avastin (R)) as Treatment of Recurrent Glioblastoma Multiforme
Martin H. Cohen et al.
ONCOLOGIST (2009)
Correlation of O6-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
Monika E. Hegi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan
Sith Sathornsumetee et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Time course of imaging changes of GBM during extended bevacizumab treatment
Suchitra Ananthnarayan et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Novel anti-angiogenic therapies for malignant gliomas
Andrew D. Norden et al.
LANCET NEUROLOGY (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Malignant gliomas in adults
Patrick Y. Wen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography:: A pilot study
Wei Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects
Dan G. Duda et al.
TRENDS IN MOLECULAR MEDICINE (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma
A Salmaggi et al.
JOURNAL OF NEURO-ONCOLOGY (2003)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung et al.
BRITISH JOURNAL OF CANCER (2000)
分享论文
